Aug 25, 2026 06:58AM
Aug 10, 2026 06:43AM
Aug 4, 2026 07:00AM
Aug 4, 2026 07:00AM
Jul 7, 2026 07:03AM
Jun 18, 2026 07:00AM
Jun 18, 2026 07:00AM Beam Therapeutics Announces Clearance of Investigational New Drug Application for BEAM-304 for the Treatment of Phenylketonuria (PKU) by the United States (U.S.) Food and Drug Administration
May 18, 2026 04:00PM
May 18, 2026 04:00PM
May 7, 2026 07:00AM
Apr 1, 2026 05:12PM
Apr 1, 2026 05:12PM
Mar 25, 2026 11:48AM
Mar 25, 2026 07:00AM Beam Therapeutics selects 60 mg dose for BEAM-302 pivotal trial
Mar 25, 2026 07:00AM
Mar 3, 2026 07:21AM
Feb 26, 2026 05:52AM
Feb 24, 2026 11:49AM
Feb 24, 2026 07:01AM
Jan 21, 2026 07:44AM
Jan 15, 2026 06:43AM H.C. Wainwright Reiterates Buy Rating on Beam Therapeutics Inc (BEAM)
Jan 12, 2026 07:25AM
Jan 12, 2026 04:04AM
Jan 11, 2026 05:00PM
Dec 9, 2025 11:57AM
Nov 4, 2025 07:00AM
Oct 31, 2025 09:54AM
Aug 30, 2025 04:00PM Why public perception matters so much for biotech valuations
Aug 14, 2025 07:00AM
Aug 14, 2025 07:00AM
Aug 5, 2025 07:00AM
Jun 3, 2025 07:00AM
Jun 3, 2025 07:00AM
May 29, 2025 04:02PM
May 29, 2025 04:01PM Beam Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)
May 12, 2025 04:05PM
May 12, 2025 04:01PM
May 6, 2025 07:00AM
Apr 10, 2025 05:32AM
Apr 5, 2025 07:00AM
Mar 27, 2025 04:01PM
Mar 27, 2025 04:01PM Beam Therapeutics Announces Clearance of Investigational New Drug Application for BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD) by the United States (U.S.) Food and Drug Administ
Mar 10, 2025 12:59PM
Mar 10, 2025 12:58PM
Jan 13, 2025 07:04AM
Jan 13, 2025 07:00AM
Jan 6, 2025 02:00PM
Nov 5, 2024 09:00AM
Nov 5, 2024 06:30AM Beam Therapeutics Reports Third Quarter 2024 Financial Results and Progress Across Priority Programs
Aug 6, 2024 06:30AM

329,907 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All